A comparative review of MSC thaw techniques, source-specific performance, and clinical implications

Introduction Mesenchymal stem cells (MSCs) are the most widely investigated cellular therapeutic in regenerative medicine. There is an increased interest in cryopreserved over-the-counter products in clinical practice. The thawing step, although often treated as trivial, has emerged as a critical determinant of post-thaw viability, immunomodulatory potency, and ultimately therapeutic efficacy. Methodology This review compares major clinical thawing techniques. These include 37 °C water bath, automated dry-warming devices, slow rewarming, body-temperature thawing, and vitrification rewarming and supplements. This review compares detailed numerical data from the primary studies using viability percentages, fold-changes, and clinical efficacy estimates. A substantially expanded source-comparison section synthesizes head-to-head data on bone marrow adipose-derived umbilical cord/Wharton’s jelly (UC/WJ), placental, and other mesenchymal stem cell sources. Results According to the previously conducted studies, UCMSCs demonstrated promising post-thaw viability (∼81% with standard 10% dimethyl sulfoxide) and favorable proliferative recovery in several studies. However, direct and standardized comparisons across MSC sources remain limited. ADMSC survival during freeze–thaw (notable loss of α4-integrin and CFU-F counts) is comparatively less than other sources. However, they exhibit the strongest immunosuppressive secretome. BMMSCs have been used extensively in clinical research and produce the most consistent angiogenic effect. However, they are cleared from the lungs faster than UCMSCs or ADMSCs. Conclusion We provide a practical, evidence-based protocol and identify potential interventions for clinical sites adopting cryopreserved MSC programs.

Authors

Publication Details

Journal
Frontiers in Drug Delivery
Published
2026-11-16
DOI
https://doi.org/10.3389/fddev.2026.1981877
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A comparative review of MSC thaw techniques, source-specific performance, and clinical implications

Sumaira, David Lawrence Greene, Umm E. Habiba, Sabiha Shamim et al.
2 links
Frontiers in Drug Delivery
Mesenchymal stem cell research
article

A comparative review of MSC thaw techniques, source-specific performance, and clinical implications

Sumaira, David Lawrence Greene, Umm E. Habiba, Sabiha Shamim, Roshini Sathyanarayanan
article en

Abstract

Introduction Mesenchymal stem cells (MSCs) are the most widely investigated cellular therapeutic in regenerative medicine. There is an increased interest in cryopreserved over-the-counter products in clinical practice. The thawing step, although often treated as trivial, has emerged as a critical determinant of post-thaw viability, immunomodulatory potency, and ultimately therapeutic efficacy. Methodology This review compares major clinical thawing techniques. These include 37 °C water bath, automated dry-warming devices, slow rewarming, body-temperature thawing, and vitrification rewarming and supplements. This review compares detailed numerical data from the primary studies using viability percentages, fold-changes, and clinical efficacy estimates. A substantially expanded source-comparison section synthesizes head-to-head data on bone marrow adipose-derived umbilical cord/Wharton’s jelly (UC/WJ), placental, and other mesenchymal stem cell sources. Results According to the previously conducted studies, UCMSCs demonstrated promising post-thaw viability (∼81% with standard 10% dimethyl sulfoxide) and favorable proliferative recovery in several studies. However, direct and standardized comparisons across MSC sources remain limited. ADMSC survival during freeze–thaw (notable loss of α4-integrin and CFU-F counts) is comparatively less than other sources. However, they exhibit the strongest immunosuppressive secretome. BMMSCs have been used extensively in clinical research and produce the most consistent angiogenic effect. However, they are cleared from the lungs faster than UCMSCs or ADMSCs. Conclusion We provide a practical, evidence-based protocol and identify potential interventions for clinical sites adopting cryopreserved MSC programs.

Frontiers in Drug DeliveryVol. 6
Good health and well-being
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon